New pilot study suggests flaxseed and low-fat diet can be protective against prostate cancer

July 10, 2001

DURHAM, N.C.--A low-fat diet supplemented with flaxseed may help reduce the risk of prostate cancer, researchers from Duke University Medical Center report in the July issue of Urology.

The researchers said dietary fat and fiber can affect hormone levels and may influence cancer progression. Flaxseed is high in fiber and is the richest source of plant-based, omega-3 fatty acids. Studies suggest that dietary fiber reduces cancer risk, and omega-3 fatty acids also have shown a protective benefit against cancer. Flaxseed is also a rich source of lignan, a specific family of fiber-related compounds that appear to play a key role in influencing both estrogen and androgen metabolism.

"We thought flaxseed would be the perfect food for prostate cancer patients," said lead author Wendy Demark-Wahnefried, associate research professor in the department of surgery at Duke. "It's full of omega-3 fatty acids, fiber and lignan. Testosterone may be important in the progression of prostate cancer, and lignan in the flaxseed binds testosterone, so we thought the flaxseed might suppress the growth of prostate cancer cells. By pairing a low-fat diet with the flaxseed supplement, we also thought we could maximize the effect of the omega-3 fatty acids, since studies in animals show that the kind of fat we eat may be important for cancer progression."

The pilot study involved 25 patients with prostate cancer who were awaiting prostatectomy (surgical removal of the prostate). Baseline levels of prostate-specific antigen (PSA), testosterone, free androgen index and total serum cholesterol were determined at the beginning of the study. The tumors of those on the diet were then matched with 25 historic cases, equal in age, race, PSA level at diagnosis and biopsy Gleason sum (a scoring system used to grade prostate tumors) to compare tumor progression and biomarkers after the dietary intervention.

The men were on the low-fat, flaxseed-supplemented diet for an average of 34 days. Finely ground flaxseed was used in the study because, in its natural form, flaxseed is a pointy, tough seed that can puncture the intestines when consumed in the amounts used in this study (three rounded tablespoons a day). The ground flaxseed in the study was vacuum-packed (ground flaxseed can quickly go rancid) and had added emulsifiers for ease of mixing. The men were instructed to sprinkle the flaxseed on their cereal or mix it into juices, yogurt or applesauce. Researchers reported good compliance with the diet and said it was tolerated well.

At the end of the study, the researchers observed that the men on the diet had significant decreases in cholesterol, and both total and free testosterone. While there was a decrease in testosterone levels, they noted that none of the participants in the study suffered decreased libido or sexual dysfunction. There was a trend toward a decrease in PSA levels in men with early-stage prostate cancer (Gleason sums of six or less), but in men with advanced prostate cancer (Gleason sums of more than six) PSA levels continued to rise.

"It's not surprising that a diet therapy that was only taken for an average of 34 days had little effect on men with aggressive disease," Demark-Wahnefried said. "But what we did see was that for the men on the diet, their tumor cells did not divide as quickly and there was a greater rate of apoptosis (tumor cell death) in this group."

With such a short-term dietary intervention, the researchers said they did not expect to see a difference in tumor biology between the diet-treated patients and the control patients, but were encouraged by the lower proliferation rates and significantly higher rates of apoptotic cell death. However, they said the results should be interpreted with caution, stressing that randomized controlled clinical trials are needed to confirm the results of the pilot study. Research on mice models is currently under way, and preliminary results support the findings in humans.

Demark-Wahnefried said it is still unknown if the low fat diet or the flaxseed--or a combination of the two--is the active component in the tumor reductions, adding more studies examining these elements independently are needed.

Note to editors: Wendy Demark-Wahnefried can be contacted at (919) 681-3261 or A photograph of Demark-Wahnefried is available at in the Medical News Service folder as "Demark-Wahnefried.jpg."

Duke University Medical Center

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to